Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection

BACKGROUND AND OBJECTIVE: VIR-2218 is an investigational N-acetylgalactosamine–conjugated RNA interference therapeutic in development for chronic hepatitis B virus (HBV) infection. VIR-2218 was designed to silence HBV transcripts across all genotypes and uses Enhanced Stabilization Chemistry Plus (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Sneha V., Fanget, Marie C., MacLauchlin, Christopher, Clausen, Valerie A., Li, Jing, Cloutier, Daniel, Shen, Ling, Robbie, Gabriel J., Mogalian, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602582/
https://www.ncbi.nlm.nih.gov/pubmed/34741731
http://dx.doi.org/10.1007/s40268-021-00369-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602582/
https://www.ncbi.nlm.nih.gov/pubmed/34741731
http://dx.doi.org/10.1007/s40268-021-00369-w

Ejemplares similares